\BOOKMARK [0][-]{Doc-Start}{Abstract}{}% 1
\BOOKMARK [0][-]{chapter*.1}{Acknowledgement}{}% 2
\BOOKMARK [0][-]{chapter*.5}{Symbols and Acronyms}{}% 3
\BOOKMARK [0][-]{chapter.1}{Introduction}{}% 4
\BOOKMARK [1][-]{section.1.1}{Drug Discovery Today}{chapter.1}% 5
\BOOKMARK [1][-]{section.1.2}{Precision Medicine}{chapter.1}% 6
\BOOKMARK [1][-]{section.1.3}{Supervised Machine Learning Methods}{chapter.1}% 7
\BOOKMARK [1][-]{section.1.4}{Machine Learning for Individualized Treatment Effects Estimation}{chapter.1}% 8
\BOOKMARK [1][-]{section.1.5}{Summary}{chapter.1}% 9
\BOOKMARK [0][-]{chapter.2}{Drug Repositioning for Psychiatric Disorders: A Machine Learning Approach Leveraging Expression Data}{}% 10
\BOOKMARK [1][-]{section.2.1}{Background}{chapter.2}% 11
\BOOKMARK [2][-]{subsection.2.1.1}{Motivation}{section.2.1}% 12
\BOOKMARK [2][-]{subsection.2.1.2}{Related Works}{section.2.1}% 13
\BOOKMARK [2][-]{subsection.2.1.3}{Significances}{section.2.1}% 14
\BOOKMARK [1][-]{section.2.2}{Datasets and Methods}{chapter.2}% 15
\BOOKMARK [2][-]{subsection.2.2.1}{Datasets}{section.2.2}% 16
\BOOKMARK [2][-]{subsection.2.2.2}{Methods}{section.2.2}% 17
\BOOKMARK [1][-]{section.2.3}{Experiment Results}{chapter.2}% 18
\BOOKMARK [2][-]{subsection.2.3.1}{Predictive performance comparison}{section.2.3}% 19
\BOOKMARK [2][-]{subsection.2.3.2}{Enrichment for psychiatric drugs considered clinical trials}{section.2.3}% 20
\BOOKMARK [2][-]{subsection.2.3.3}{Correlation of predicted probabilities with degree of literature support}{section.2.3}% 21
\BOOKMARK [2][-]{subsection.2.3.4}{Identifying contributing genes and pathways}{section.2.3}% 22
\BOOKMARK [2][-]{subsection.2.3.5}{Top repositioning hits and literature support from previous studies}{section.2.3}% 23
\BOOKMARK [1][-]{section.2.4}{Discussion}{chapter.2}% 24
\BOOKMARK [1][-]{section.2.5}{Conclusion}{chapter.2}% 25
\BOOKMARK [0][-]{chapter.3}{A Machine Learning Approach to Prioritizing Candidate Drug Targets for Complex Diseases}{}% 26
\BOOKMARK [1][-]{section.3.1}{Introduction}{chapter.3}% 27
\BOOKMARK [2][-]{subsection.3.1.1}{Motivation}{section.3.1}% 28
\BOOKMARK [2][-]{subsection.3.1.2}{Related Works}{section.3.1}% 29
\BOOKMARK [1][-]{section.3.2}{Datasets and Methods}{chapter.3}% 30
\BOOKMARK [2][-]{subsection.3.2.1}{Datasets}{section.3.2}% 31
\BOOKMARK [2][-]{subsection.3.2.2}{Methods}{section.3.2}% 32
\BOOKMARK [1][-]{section.3.3}{Results}{chapter.3}% 33
\BOOKMARK [2][-]{subsection.3.3.1}{Model Performance}{section.3.3}% 34
\BOOKMARK [2][-]{subsection.3.3.2}{External Validation}{section.3.3}% 35
\BOOKMARK [2][-]{subsection.3.3.3}{Literature Support}{section.3.3}% 36
\BOOKMARK [1][-]{section.3.4}{Discussion}{chapter.3}% 37
\BOOKMARK [1][-]{section.3.5}{Conclusion}{chapter.3}% 38
\BOOKMARK [0][-]{chapter.4}{Evaluating Individualized Treatment Effects \(ITE\) of Risk Factors on Patient Outcomes}{}% 39
\BOOKMARK [1][-]{section.4.1}{Motivation}{chapter.4}% 40
\BOOKMARK [1][-]{section.4.2}{Background}{chapter.4}% 41
\BOOKMARK [1][-]{section.4.3}{Overview of Related Work}{chapter.4}% 42
\BOOKMARK [2][-]{subsection.4.3.1}{Background Methods}{section.4.3}% 43
\BOOKMARK [2][-]{subsection.4.3.2}{Causal Forests}{section.4.3}% 44
\BOOKMARK [1][-]{section.4.4}{ITE Framework}{chapter.4}% 45
\BOOKMARK [2][-]{subsection.4.4.1}{Novel Tests for the presence of heterogeneity}{section.4.4}% 46
\BOOKMARK [2][-]{subsection.4.4.2}{Modeling Survival Outcomes}{section.4.4}% 47
\BOOKMARK [1][-]{section.4.5}{Experiment Results}{chapter.4}% 48
\BOOKMARK [2][-]{subsection.4.5.1}{Simulations Studies}{section.4.5}% 49
\BOOKMARK [2][-]{subsection.4.5.2}{Applications to Real Data}{section.4.5}% 50
\BOOKMARK [1][-]{section.4.6}{Conclusion}{chapter.4}% 51
\BOOKMARK [0][-]{chapter.5}{Conclusions}{}% 52
\BOOKMARK [0][-]{appendix.A}{Proof of Propositions}{}% 53
\BOOKMARK [0][-]{appendix.B}{Publication List}{}% 54
\BOOKMARK [0][-]{appendix.B}{Bibliography}{}% 55
